Trimipramine Maleate + AlcoholModerate
Concomitant use of alcoholic beverages may be associated with exaggerated effects of trimipramine maleate.
Source: NLP:trimipramine maleate
Trimipramine Maleate Interactions
Brand names: Trimipramine Maleate
Route: Oral
FDA Black Box Warning
Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of trimipramine maleate or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Trimipramine maleate is not approved for use in pediatric patients. (See WARNINGS - Clinical Worsening and Suicide Risk , PRECAUTIONS: Information for Patients , and PRECAUTIONS: Pediatric Use .)
Contraindications
CONTRAINDICATIONS Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with trimipramine maleate or within 14 days of stopping treatment with trimipramine maleate is contraindicated because of an increased risk of serotonin syndrome. The use of trimipramine maleate within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting trimipramine maleate in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRTION ). Hypersensitivity to Tricyclic Antidepressants Cross-sensitivity between trimipramine maleate and other dibenzazepines is a possibility. Myocardial Infarction The drug is contraindicated during the acute recovery period after a myocardial infarction.
Pregnancy & Breastfeeding
Pregnancy Teratogenic Effects Trimipramine maleate has shown evidence of embryotoxicity and/or increase incidence of major anomalies in rats or rabbits at doses 20 times the human dose. There are no adequate and well-controlled studies in pregnant women. Trimipramine maleate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
11 interactions on record
Trimipramine Maleate + AtropineModerate
Atropine-like effects may be more pronounced in patients receiving trimipramine maleate. Particular care should be exercised when administering together.
Source: NLP:trimipramine maleate
Cimetidine inhibits elimination of trimipramine maleate. Downward dosage adjustment may be required if cimetidine is initiated; upward adjustment if discontinued.
Source: NLP:trimipramine maleate
Tricyclic antidepressants potentiate catecholamine effects. Local anesthetics containing epinephrine require particular care when used with trimipramine maleate.
Source: NLP:trimipramine maleate
Flecainide inhibits cytochrome P450 2D6, increasing trimipramine maleate plasma concentrations and risk of toxicity.
Source: NLP:trimipramine maleate
Fluoxetine inhibits P450 2D6 and increases trimipramine maleate concentrations. Caution is indicated in co-administration. Sufficient time must elapse before initiating trimipramine in patients withdrawn from fluoxetine.
Source: NLP:trimipramine maleate
Paroxetine inhibits P450 2D6, potentially increasing trimipramine maleate concentrations. Caution is indicated in co-administration.
Source: NLP:trimipramine maleate
Propafenone inhibits cytochrome P450 2D6, increasing trimipramine maleate plasma concentrations and risk of toxicity.
Source: NLP:trimipramine maleate
Trimipramine Maleate + QuinidineModerate
Quinidine inhibits cytochrome P450 2D6, reducing trimipramine maleate metabolism and increasing plasma concentrations. Patient may become abruptly toxic.
Source: NLP:trimipramine maleate
Sertraline inhibits P450 2D6, potentially increasing trimipramine maleate concentrations. Caution is indicated in co-administration.
Source: NLP:trimipramine maleate
Tricyclic antidepressants can potentiate the effects of sympathomimetic amines. Particular care should be exercised when administering together.
Source: NLP:trimipramine maleate